---
schema_version: "secwatch.filing_event.v1"
accession: "0001666071-23-000026"
form_type: "8-K"
ticker: "CDLX"
cik: "0001666071"
company_name: "Cardlytics, Inc."
filed_at: "2023-03-01T23:59:59+00:00"
generated_at: "2026-06-18T18:11:44.346638+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cardlytics Q4 revenue down 8.4% to $82.5M; GAAP net loss $378.3M, guides Q1 weak

## Summary
- Q4 revenue $82.5M (-8.4% YoY); net loss $(378.3)M or $(11.32)/diluted share vs $(0.35) in Q4 2021.
- Non-GAAP net loss $(9.7)M ($(0.29)/share) vs $(5.0)M ($(0.15)) in Q4 2021.
- Adjusted EBITDA loss $(6.1)M vs positive $2.6M in Q4 2021; full year adjusted EBITDA loss $(45.2)M.
- Q1 2023 guidance: revenue $54-63M, adjusted EBITDA loss $(17)-$(10)M.
- Bridg ARR $23.1M (+51.3% YoY); MAUs 182.7M (+4.2%); ARPU $0.45 (-7.8%).

## SEC filing metadata
- accession: 0001666071-23-000026
- form_type: 8-K
- ticker: CDLX
- cik: 0001666071
- company_name: Cardlytics, Inc.
- filed_at: 2023-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1666071/000166607123000026/0001666071-23-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1666071/000166607123000026/cdlx-20230301.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001666071-23-000026
- JSON: https://secwatch.observer/filing/0001666071-23-000026.json
- Plain text: https://secwatch.observer/filing/0001666071-23-000026.txt

## Key facts
- Earnings Releases
  Cardlytics, Inc. reported the first quarter of 2023 results: revenue $54.0 - $63.0. Guidance initiated.
  - Period: the first quarter of 2023
  - Revenue: $54.0 - $63.0
  - Guidance: initiated
  - Result: guidance update
  source text: Cardlytics anticipates billings, revenue, and adjusted contribution to be in the following ranges (in millions): Q1 2023 Guidance Billings (1) $84.0 - $93.0 Revenue $54.0 - $63.0 Adjusted contribution (2) $26.0 - $31.0 Adjusted EBITDA (3) ($17.0) - ($10.0)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1666071/000166607123000026/0001666071-23-000026-index.htm
- Earnings Releases
  Cardlytics, Inc. reported the fiscal year ended December 31, 2022 results: revenue $298.5 million, net income $(465.3) million, EPS $(13.92) per diluted share.
  - Period: the fiscal year ended December 31, 2022
  - Revenue: $298.5 million
  - Net income: $(465.3) million
  - EPS: $(13.92) per diluted share
  - Result: reported results
  source text: Total revenue was $298.5 million, an increase of 11.8%, compared to $267.1 million in 2021. • Net loss attributable to common stockholders was $(465.3) million, or $(13.92) per diluted share, based on 33.4 million weighted-average common shares outstanding, compared to a net loss attributable to common stockholders of $(128.6) million, or $(3.99) per diluted share, based on 32.2 million weighted-average common shares outstanding in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1666071/000166607123000026/0001666071-23-000026-index.htm
- Earnings Releases
  Cardlytics, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $82.5 million, net income $(378.3) million, EPS $(11.32) per diluted share.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: $82.5 million
  - Net income: $(378.3) million
  - EPS: $(11.32) per diluted share
  - Result: reported results
  source text: Total revenue was $82.5 million, a decrease of (8.4)%, compared to $90.0 million in the fourth quarter of 2021. • Net loss attributable to common stockholders was $(378.3) million, or $(11.32) per diluted share, based on 33.4 million weighted-average common shares outstanding, compared to a net loss attributable to common stockholders of $(11.8) million, or $(0.35) per diluted share, based on 33.4 million weighted-average common shares outstanding in the fourth quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1666071/000166607123000026/0001666071-23-000026-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.